Arcus Biosciences, Inc.

ABOUT

Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer.

Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

3928 Point Eden Way, Hayward, CA 94545 1800 Sierra Point Parkway, Brisbane, CA 94005 US

Email Us

NEWS

Business

Investment Banking Prowess Paved Jennifer Jarrett’s Path to Arcus Biosciences

“I hope to thread the needle between pricing responsibly and achieving profitability,” Jarrett said.

November 21, 2021

4 min read

Gail Dutton

Business

Gilead Goes All in On Arcus Option Deal Totaling $725 Million

Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.

November 18, 2021

3 min read

Mark Terry

Drug Development

Arcus is Uncloaking Cancer with Well-Informed Optimism

This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.

October 10, 2021

4 min read

Gail Dutton

Business

Arcus Biosciences CMO Jumps to Gilead Sciences After 10-Year Oncology Pact

Shares of Arcus Biosciences dipped sharply in post-market trading Monday after it was learned that the company’s chief medical officer was departing for a role at Gilead Sciences.

July 20, 2021

2 min read

Alex Keown

Biotech Bay

Bay Area Biotech Companies Hiring Now

The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.

July 15, 2021

6 min read

Heather McKenzie

Cavallini James/BSIP/Universal Images Group via Ge

Drug Development

Arcus Preps for Phase III with “Encouraging” Response Rates for NSCLC Immunotherapy

The first interim analysis of a three-arm Phase II ARC-7 trial shows Arcus Biosciences’ anti-TIGIT immunotherapy combination features “encouraging clinical activity” as an initial therapy for patients with metastatic non-small cell lung cancer (NSCLC).

June 24, 2021

2 min read

Brandon May

Drug Development

ASCO Update: A Theme of Accessibility and Pricing Plus Individual Reporting

With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.

June 4, 2021

4 min read

Mark Terry

Drug Development

Clinical Catch-Up: January 11-15

The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.

January 15, 2021

4 min read

Mark Terry

Business

AstraZeneca and Arcus Biosciences Pair Assets in NSCLC Study

Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.

October 29, 2020

3 min read

Alex Keown

AWARDS